57229-37-5

Basic information

• Product Name: pyrazinuric acid
• Synonyms: pyrazinuric acid
• CAS NO: 57229-37-5
• Molecular Formula: C₇H₇N₃O₃
• Molecular Weight: 181.14878
• Mol File: 57229-37-5.mol
• Article Data: 6

Chemical Properties

• Melting Point: 229-230 °C
• Boiling Point: 537.1°Cat760mmHg
• Flash Point: 278.6°C
• Appearance: /
• Density: 1.422g/cm³
• Vapor Pressure: 2.29E-12mmHg at 25°C
• Refractive Index: 1.577
• PKA: 3.08±0.10(Predicted)
• CAS DataBase Reference: pyrazinuric acid(CAS DataBase Reference)
• NIST Chemistry Reference: pyrazinuric acid(57229-37-5)
• EPA Substance Registry System: pyrazinuric acid(57229-37-5)

Safety Data

• Hazardous Substances Data: 57229-37-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C7H7N3O3/c11-6(12)4-10-7(13)5-3-8-1-2-9-5/h1-3H,4H2,(H,10,13)(H,11,12)

Upstream product

• 19847-10-0 pyrazinoyl chloride 
• 56-40-6 glycine 
• 6164-79-0 methyl pyrazine-2-carboxylate 
• 98-97-5 2-pyrazylcarboxylic acid 
• 117904-01-5 (N-(methoxycarbonylmethyl)-carboxamido)-pyrazine 
• 7364-42-3 N,O-bis(trimethylsilyl)glycine 
• 103435-88-7 pyrazinecarboxylic acid imidazolide 
• 306990-94-3 (1H-benzo[d][1,2,3]triazol-1-yl)(pyrazin-2-yl)methanone 

Relevant articles and documents

Syntheses of some N-(pyrazinecarbonyl)amino acids and peptides

Derivatives of some amino acids, having a pyrazinecarbonyl or 3-aminopyrazinecabonyl radical, have been synthesized and some peptides prepared.In the case of the 3-aminopyrazinecarbonyl derivatives, condensed pyrimidines, i.e. 4(3H)-pteridinone derivatives, could be prepared.

N-Pyrazinoyl substituted amino acids as potential antimycobacterial agents-the synthesis and biological evaluation of enantiomers

Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis (Mtb), each year causing millions of deaths. In this article, we present the synthesis and biological evaluations of new potential antimycobacterial compounds containing a fragment of the first-line antitubercular drug pyrazinamide (PZA), coupled with methyl or ethyl esters of selected amino acids. The antimicrobial activity was evaluated on a variety of (myco)bacterial strains, including Mtb H37Ra, M. smegmatis, M. aurum, Staphylococcus aureus, Pseudomonas aeruginosa, and fungal strains, including Candida albicans and Aspergillus flavus. Emphasis was placed on the comparison of enantiomer activities. None of the synthesized compounds showed any significant activity against fungal strains, and their antibacterial activities were also low, the best minimum inhibitory concentration (MIC) value was 31.25 μM. However, several compounds presented high activity against Mtb. Overall, higher activity was seen in derivatives containing l-amino acids. Similarly, the activity seems tied to the more lipophilic compounds. The most active derivative contained phenylglycine moiety (PC-d/l-Pgl-Me, MIC 1.95 μg/mL). All active compounds possessed low cytotoxicity and good selectivity towards Mtb. To the best of our knowledge, this is the first study comparing the activities of the d- and l-amino acid derivatives of pyrazinamide as potential antimycobacterial compounds.

Bortezomib congeners induce apoptosis of hepatocellular carcinoma via CIP2A inhibition

CIP2A is an oncoprotein that upregulates p-Akt and promotes cancer cell proliferation and survival. The proteasome inhibitor bortezomib has been shown to reduce CIP2A and lead to cell apoptosis. Here; we modified the functional group of bortezomib to generate a series of novel compounds and conducted a structure-activity relationship (SAR) study. The results showed that compound 1 was able to repress CIP2A expression and cell apoptosis in the same manner as bortezomib, but with less potency in inhibition of proteasome activity. This finding provides a new direction for the design of CIP2A inhibitors.